Biotech Oncology

Sector thesis

Biotech oncology is the business of developing drugs and therapies to treat cancer. Companies in this space run clinical trials, file for FDA approval, and if successful, sell medicines to hospitals and patients. It's one of the highest-risk, highest-reward corners of biotech. Why now? Cancer rates are rising globally as populations age, and survival times are improving—meaning more patients live longer and need ongoing treatment. At the same time, the science is shifting. Instead of one-size-fits-all chemotherapy, we're moving toward personalized medicine: drugs designed for specific genetic mutations in a patient's tumor, or therapies that train the immune system to fight cancer itself. This precision approach works better and causes fewer side effects, which means patients tolerate it longer and doctors prescribe it more readily. The sector breaks into three main buckets: small-molecule drugs (traditional pills), biologics (proteins made from living cells, often injected), and cell therapies (where doctors reprogram a patient's own immune cells to attack tumors). Each has different timelines, costs, and approval pathways. The biggest risk is clinical failure. A drug can look promising in early tests but flop in large human trials, wiping out years of investment. Approval is never guaranteed, and even approved drugs face competition and pricing pressure. Smaller biotech firms often have one or two shots—if their lead drug fails, the stock can collapse. For a retail portfolio, oncology biotech is typically a small, high-conviction position, not a core holding. Watch for clinical trial results (companies announce these regularly), FDA decisions, and partnerships with larger pharma firms—those validate science and reduce risk. Diversify across stage: some early-stage bets, some late-stage closer to approval. Accept that volatility is the price of entry.